What Investors Should Know About a $163K AnaptysBio Insider Sale

This clinical-stage biotech specializing in antibody therapeutics reported a notable insider sale amid ongoing development and partnerships.Paul F. Lizzul, the chief medical officer of AnaptysBio (ANAB +1.99%), reported the direct sale of 3,650 shares of the company for a total consideration of approximately $163,191.50 on Thursday, as disclosed in a recent SEC Form 4 filing.Transaction summaryMetricValueShares sold (direct)3,650Transaction value$163,191.50Post-transaction shares (direct)42,088Post-transact ...